Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e17035
Abstract: e17035Background: CD47 is an antiphagocytic signal and macrophage checkpoint that bladder and other cancer cells over-express to evade innate immunity. Magrolimab (Hu5F9-G4) a CD47 blocking antibod... read more here.
Keywords: bladder cancer; bladder; cisplatin combination; magrolimab gemcitabine ... See more keywords